antibody engineering

AbbraTech is a life science company founded in 2020 in Branford, Connecticut, by experienced life science industry researchers. Its mission is to enable discovery of antibodies against drug targets beyond the reach of conventional approaches. Its EPIVOLVE technology is a generalizable platform capable of driving antibody recognition of any exposed region of a target protein, regardless of the underlying sequence. The company works with industry and academic partners to discover next-generation medicines.

antibody discoveryantibody validationB cell cloningimmunorepertoire analysisphage display

Abwiz Bio is a fee-for-service antibody lab founded in 2012 with a PhD-led scientific team. It specializes in antibody engineering, including STEM™ staged affinity maturation and RabWiz™ rabbit immunization paired with phage display, plus antibody humanization and optimization. The company holds a patented WizAmp™ library construction method (US Pat. 9,890,414) and sells recombinant rabbit monoclonal antibodies, phospho antibodies, cell surface antibodies, and SARS-CoV-2 antibodies and proteins.

affinity maturationantibody humanizationantibody optimizationcell-based phage display panninglibrary constructionphage displayrabbit immunization

Æona Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, focused on developing human antibody therapeutics. It is advancing the antibody therapeutic AE-101 to address Rhabdomyosarcoma (RMS) and Malignant Fibrous Histiocytoma (MFH). The company uses an AI-driven antibody engineering platform combining computational protein design, in silico screening, and wet lab techniques to develop targeted biological therapeutics.

AI and machine learning drug discoveryantibody discoverycomputational protein designin silico screeningwet lab engineering

Antibody Design Labs is a San Diego-based provider of phage display and antibody discovery products and services. With more than 30 years of experience, the company offers peptide and antibody phage display libraries, helper phages, phagemid and phage vectors, yeast display vectors, competent cells, and TGEX antibody expression vectors, along with services including peptide discovery, library construction, antibody discovery, engineering, reformatting, and expression.

affinity maturationantibody humanizationantibody library constructionantibody reformattingimmunizationlibrary screeningmammalian cell expressionmolecular cloningpeptide library constructionphage displayphage display library constructiontransient antibody expressionyeast display

Aragen Bioscience is a biologics research and development partner for biotechnology companies worldwide, offering discovery, development, and manufacturing services. It has three decades of experience and operates with a US-India model, with a facility in Morgan Hill, California and operations in Bengaluru, India. Its services span cell line development, bioproduction, process development, analytical development, formulation development, and GMP biologics manufacturing.

analytical development and characterisationbioproductioncell line developmentformulation developmentGMP biologics manufacturinghistology and digital pathologyimmunology and in vitro pharmacologypreclinical efficacy testingprocess developmentrecombinant protein production

AvantGen is a San Diego-based biotechnology company that enables scientific partners in the discovery and optimization of novel antibody drugs. It uses a proprietary yeast display system and its Germliner™ Library Collection to provide fully human antibody platforms with more than 100 billion antibody clones, and offers affinity maturation and antibody engineering services.

affinity maturationantibody discoverybioconjugationcell sorting based screeninglibrary designQCrabbit monoclonal antibody generationrecombinant expression in HEK293 or CHO cellsyeast display

BioCopy AG is a multinational biotechnology company headquartered in Basel, Switzerland, with an R&D facility in Emmendingen, Germany. Founded in 2019, it combines antibody engineering with data science and AI in an integrated wet-lab and digital discovery model to unlock challenging intracellular cancer targets and develop next-generation TCR(m)-based immunotherapeutics.

AI-driven predictionantibody lead discoveryantibody lead optimizationhigh throughput screeningstructural modelingtarget credentialingwet-lab validation

Biorbyt is a life science supplier based in Cambridge, UK, offering over 500,000 high-quality bioreagents including antibodies, proteins, ELISA kits, small molecules and molecular biology tools for immunology, neuroscience, cancer biology and related research fields. The company holds ISO 9001 certification and received the Queen's Award in 2021, and reports having delivered over 1,000,000 bio-reagents to life science researchers.

animal models & technical servicesantibody conjugationcell biology servicescustom antibody developmentcustom peptide synthesiscustom recombinant antibody productionmembrane protein & ECD expressionmolecular biology servicespathology testing servicesrecombinant protein expressionVHH antibody (nanobody) production

Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company that has pioneered an innovative platform technology focused on development and commercialization of a novel class of orally delivered polyclonal antibodies for enteric disease prevention and treatment. Founded and incorporated in Australia in 1994, it has been listed on the ASX since April 30, 1999 under the symbol IMC, and its ADSs and warrants are listed on NASDAQ under IMRN and IMRNW.

clinical developmentdevelopment and commercialisation of polyclonal antibodiesmanufacturing process development

Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases. By pairing state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering techniques, it develops a pipeline of product candidates for prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. It deploys a proprietary integrated technology platform to create best-in-class antibodies.

monoclonal antibody developmentpredictive modelingviral surveillance